- Home
- ATLN vs DRUG Comparison
ATLN vs DRUG Comparison
Compare ATLN & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLN
- DRUG
- Stock Information
- Founded
- ATLN 2014
- DRUG 2019
- Country
- ATLN United States
- DRUG United States
- Employees
- ATLN N/A
- DRUG N/A
- Industry
- ATLN
- DRUG Pharmaceuticals and Biotechnology
- Sector
- ATLN
- DRUG Health Care
- Exchange
- ATLN NYSE
- DRUG Nasdaq
- Market Cap
- ATLN 269.5M
- DRUG 260.6M
- IPO Year
- ATLN 2021
- DRUG N/A
- Fundamental
- Price
- ATLN $3.53
- DRUG $37.65
- Analyst Decision
- ATLN
- DRUG Strong Buy
- Analyst Count
- ATLN 0
- DRUG 4
- Target Price
- ATLN N/A
- DRUG $84.33
- AVG Volume (30 Days)
- ATLN 32.2K
- DRUG 91.2K
- Earning Date
- ATLN 01-01-0001
- DRUG 12-31-2024
- Dividend Yield
- ATLN N/A
- DRUG N/A
- EPS Growth
- ATLN N/A
- DRUG N/A
- EPS
- ATLN N/A
- DRUG N/A
- Revenue
- ATLN $429,260,149.00
- DRUG N/A
- Revenue This Year
- ATLN N/A
- DRUG N/A
- Revenue Next Year
- ATLN N/A
- DRUG N/A
- P/E Ratio
- ATLN N/A
- DRUG N/A
- Revenue Growth
- ATLN 5.50
- DRUG N/A
- 52 Week Low
- ATLN $1.30
- DRUG $0.93
- 52 Week High
- ATLN $8.98
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- ATLN N/A
- DRUG 55.50
- Support Level
- ATLN N/A
- DRUG $28.21
- Resistance Level
- ATLN N/A
- DRUG $38.00
- Average True Range (ATR)
- ATLN 0.00
- DRUG 2.86
- MACD
- ATLN 0.00
- DRUG 0.45
- Stochastic Oscillator
- ATLN 0.00
- DRUG 96.42
About ATLN ATLANTIC INTERNATIONAL CORP
Atlantic International Corp formerly SeqLL Inc is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields. The company leverages its expertise with the True Single Molecule Sequencing platform to empower scientists and researchers with improved genetic tools to greater understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with precision medicine.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.